MedTrace Logo

Evaluation of Strongyloidiasis in Ecuador: a fieLd Laboratory Accuracy Study

NCT04999774 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 781

Last updated 2022-11-03

No results posted yet for this study

Summary

the World Health Organization (WHO) has recently committed to promote the control of strongyloidiasis within 2030 targets for STH control programmes. A specific target is to establish by 2030 an efficient strongyloidiasis control programme in school aged children (SAC), envisaging ivermectin preventive chemotherapy (PC) of SAC at risk of morbidity due to strongyloidiasis. The monitoring of such ambitious PC activity strictly requires appropriate diagnostic tools, but fundamental gaps exist in this field. Indeed, until now at the moment no consensus method for the diagnosis of S. stercoralis infection is recommended and the absence of a gold standard test limits capacity for effective diagnosis, surveillance and disease control. The aim of this project is to provide fundamental information on the performance and applicability of diagnostic methods for the assessment of S. stercoralis infection to inform the forthcoming WHO global strongyloidiasis control program to be implemented as a part of the WHO 2030 disease control targets. ESTRELLA is a cross-sectional study in an area of high prevalence of strongyloidiasis (San Lorenzo, Esmeraldas, Ecuador). The study will have a school-based approach, and each enrolled SAC will be asked to supply fecal and blood samples for testing with different methods for the diagnosis of S. stercoralis infection.

Conditions

  • Strongyloidiasis
  • Strongyloides Stercoralis Infection

Interventions

DIAGNOSTIC_TEST

Different diagnostic tests

Each SAC will be tested with all tests

Sponsors & Collaborators

  • CECOMET (Centro de Epidemiologia Comunitaria y Medicina Tropical)

    collaborator UNKNOWN

  • Universidad Central del Ecuador

    collaborator OTHER

  • World Health Organization

    collaborator OTHER

  • IRCCS Sacro Cuore Don Calabria di Negrar

    lead OTHER

Principal Investigators

  • Angel Guevara · Universidad Central del Ecuador

  • Dora Buonfrate · IRCCS Sacro Cuore Don Calabria hospital

Eligibility

Min Age
6 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-06
Primary Completion
2022-06-11
Completion
2022-06-11
FDA Device
Yes

Countries

  • Ecuador

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04999774 on ClinicalTrials.gov